FATE THERAPEUTICS INC 8K

Fate Therapeutics reported Q2 2026 results, advanced multiple iPSC‑derived CAR T programs including a potentially registrational FT819 lupus nephritis trial and an IND‑cleared FT839 basket trial, added a new director, and guided to a cash runway into 2028 despite ongoing net losses.

Fate Therapeutics, Inc. reported its second quarter 2026 financial results and provided business updates, highlighting dosing of the first lupus nephritis patient in RECLAIM-LN, a Phase 2 potentially registrational trial of its iPSC-derived off-the-shelf CAR T-cell therapy FT819, FDA clearance of an IND for next‑generation dual‑targeting CAR T candidate FT839 to enter a Phase 1/2 basket trial in autoimmune diseases, encouraging preliminary clinical data for FT819 in systemic lupus erythematosus and systemic sclerosis as well as for FT836 in colorectal cancer, the appointment of Laura Hamill to the Board of Directors, and a financial position of $153.8 million in cash, cash equivalents, and investments with quarterly net loss of $30.2 million and an expected cash runway into 2028 driven by reduced operating expenses.

Filing Facts

CIK

1434316

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-347984

Alert Tier

6